Morningstar
•
May 28, 2026
AbbVie Inc.: AbbVie Earnings: Shares Remain Fairly Valued; Immunology Portfolio and Pipeline Look Solid
Summary
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 20
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
The Argus Sustainable Growth Theme Model Portfolio
May 28, 2026
•
TT, GOOGL, DE, AAPL, NDAQ, AVGO, ADI, JPM, JNJ, MRK, TXN, MSFT, TFC, GLW, MA, LLY, TRV, SPGI, GE, NVDA, NOC, KO, KMI, AEP, GS, ECL, TMUS, ETN, AMZN, WMT
O: Raising target price to $69.00
May 27, 2026
•
O
Analyst Report: 3M Company
May 26, 2026
•
MMM
Analyst Report: Eli Lilly and Company
May 22, 2026
•
LLY
O: Lowering target price to $68.00
May 20, 2026
•
O
Analyst Profile
Karen Andersen
Sector Strategist
Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is responsible for biotechnology research.Before joining Morningstar in 2005, Andersen received a master’s degree in business administration from Rice University, where she served as senior healthcare analyst for the M.A. Wright Fund and earned the distinction of Jones Scholar. She has scientific research experience in both academia (at Rice University and the University of Queensland in Australia) and industry (at Lexicon Genetics and a subsidiary of Genzyme).Andersen also holds a bachelor’s degree in biochemistry from Rice University, where she graduated magna cum laude. She is a member of Phi Beta Kappa and holds the Chartered Financial Analyst® designation. She ranked first in the biotechnology industry, and had the highest score overall, in The Wall Street Journal’s annual “Best on the Street” analysts survey in 2013, the last year the survey was conducted.
